Mortality In Patients With Acute Myeloid Leukemia Doubles In COVID-19 - Expert

Table of contents:

Mortality In Patients With Acute Myeloid Leukemia Doubles In COVID-19 - Expert
Mortality In Patients With Acute Myeloid Leukemia Doubles In COVID-19 - Expert

Video: Mortality In Patients With Acute Myeloid Leukemia Doubles In COVID-19 - Expert

Video: Mortality In Patients With Acute Myeloid Leukemia Doubles In COVID-19 - Expert
Video: Acute Myeloid Leukemia: Navigating Treatment Paradigm Shifts and Disease Heterogeneity 2023, December
Anonim

Mortality in patients with acute myeloid leukemia doubles in COVID-19 - expert

According to Russian hematologists, the pandemic puts patients with AML, the most aggressive form of leukemia, at great risk.

Mortality in patients with acute myeloid leukemia doubles in COVID-19 - expert
Mortality in patients with acute myeloid leukemia doubles in COVID-19 - expert

Photo: CC0 Public Domain 1026

As Kamil Kaplanov, head of the hematology department of the Volgograd Regional Clinical Oncological Dispensary, said during an online conference on topical AML issues, the pandemic did not affect the quality of diagnosis of AML patients, but created great difficulties in the treatment of the primary disease.

“Over the years, we have built a system so that even if a patient is in an intensive condition in an infectious diseases clinic or in neuroreanimation, we will be able to quickly take material for research. Treatment for the primary patient is more difficult. I have not yet faced a dilemma when I have a patient with an acute illness and at the same time he is diagnosed with covid, but in the group of elderly patients I have three such people. Each time the management of such patients creates enormous difficulties for the staff,”said the doctor.

According to Elena Parovichnikova, head of the department of chemotherapy of hemoblastosis, hematopoietic depression and BMT at the National Medical Research Center of Hematology, the COVID-19 pandemic has made serious adjustments to the treatment of oncohematological patients throughout the country. An observational department has been organized in each medical center, the rules for diagnostics and testing have changed. In some regions, hematology departments based on large centers were disbanded and transferred to small medical institutions.

“So far we have not seen a big catastrophe in the organization of our work. But if a patient is diagnosed with acute leukemia and has received chemotherapy, with COVID-19 the mortality rate doubles. In our center, the mortality rate from AML is on average 7%, in patients under 60 years of age - 3-4%. But in those patients who underwent treatment, and then fell ill with coronavirus and were transferred to covid departments, the mortality rate is about 15-20%, Parovichnikova said.

The doctor also noted that the National Medical Research Center of Hematology has initiated a large observational study, which will analyze all reported cases of hemoblastosis, including acute leukemia, in combination with COVID-19. The study has already been registered and will begin shortly.

“This will allow us to get more objective information on how the pandemic affected such patients,” said Elena Parovichnikova.

Acute myeloid leukemia is a clonal tumor disease of the hematopoietic tissue caused by a mutation in the genetic material of the hematopoietic cell. In most cases, the cause of the disease remains unknown. It is believed that AML falls ill annually on average 3-5 people per 100 thousand population. At the same time, the incidence increases sharply at the age of over 60 and amounts to 12-13 cases per 100 thousand of the population in persons over the age of 80. With a conditional population of 140 million inhabitants in Russia, the estimated incidence rate (according to European and American researchers) should be about 5 thousand cases. According to the results of a registration study carried out by a Russian research group for the study of acute leukemia in a number of regions of Russia, the median age of AML diagnosis is 53 years.which is more than 10 years less than in Western countries. These indicators indicate both the insufficient diagnosis of AML in patients of the older age group, and the shorter life expectancy of the population in our country.

Recommended: